AL Amyloidosis research hub

A phase 2, open label, multicenter, single-stage study to evaluate the efficacy of Isatuximab plus Pomalidomide and Dexamethasone (IPd), in patients with AL amyloidosis not in VGPR or better after any previous therapy

This study is testing a new combination of medicines for people with AL amyloidosis. It looks at how well the new treatment works and if it helps improve the disease, especially for those who haven't responded well to previous treatments.

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

This study investigates a new treatment, CAEL-101, for a serious heart condition called AL amyloidosis. Researchers want to see if CAEL-101 can help patients live longer and reduce hospital stays, alongside their usual medicine, compared to a dummy drug.

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

This study is testing a new medicine, CAEL-101, for people with a serious heart condition called AL amyloidosis. Researchers want to see if it helps people live longer, reduces hospital stays, and is safe when added to standard treatment.

National Registry of Rare Kidney Diseases

This registry is collecting information from people with rare kidney diseases across the UK. It aims to improve understanding, create better care guidelines, and help develop new treatments for these conditions. If you have a rare kidney disease, your information could help.

ETCABio - Evaluation of Skin Tests in Biotherapy Allergies

This study looks at how your skin reacts to certain advanced cancer medicines, called biotherapies. We're finding the strongest dose that doesn't cause a skin reaction in most people when tested on the skin, to make these treatments safer.

An open-label, multi-center, non-randomized pivotal Phase 3 study to evaluate the efficacy and safety of [18F]florbetaben Positron Emission Tomography (PET) imaging to diagnose cardiac AL amyloidosis